Interlid specializes in conducting thorough clinical and commercial due diligence for EIC-funded companies, focusing on innovative healthcare ventures. Our mission is to empower these high-potential startups and scale-ups by validating their innovations, mitigating risks, and unlocking pathways to sustainable growth and commercialization in competitive global markets. In the clinical due diligence phase, our expert team, comprising scientific, clinical, financial and market access experts, evaluates the scientific and clinical foundation of the technology. This includes a deep analysis of clinical trial design and data, efficacy and safety profiles, intellectual property strength, and compliance with international standards like EMA and FDA regulations. We assess proof-of-concept results identifying potential gaps in validation, potential ethical concerns, and opportunities for clinical oversight or reference center recruitment. Leveraging our global network, we conduct comparative analyses of clinical guidelines and engage with key stakeholders, including payers and decision-makers, to ensure robust evidence for market access.

On the commercial side, we scrutinize business models, market analyses, and go-to-market strategies tailored to EIC Accelerator recipients. This encompasses feasibility assessments, market analysis, sales forecasting, competitive landscape reviews, and financial valuations. We do provide as well insights into investment rounds, negotiations and merger and acquisition processes, drawing from our wide and global experience in the sector both with companies and investors. Our personalized services ensure excellence, driving breakthroughs that enhance economic value both for companies involved in investment processes and for venture capital seeking to have an independent analysis of their potential investment opportunities.